2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Vecta Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms VECAM 40/300, Esomeprazole 20 mg - Gastroesophageal Reflux | Phase 2 | Completed | Vecta Ltd. | 52 | 2009-12-01 | 2012-07-30 |
| Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH Omeprazole, Vecam - Gastroesophageal Reflux | Phase 1 | Completed | Vecta Ltd. | 60 | 2008-12-01 | 2010-01-27 |
Gastroesophageal Reflux (2) · Heartburn (2)
Esomeprazole (1) · Omeprazole (1)
United States (2)
Vijayalakshmi S Pratha, MD (1)